ATE181962T1 - Klonierte glutaminsäuredekarboxylase - Google Patents

Klonierte glutaminsäuredekarboxylase

Info

Publication number
ATE181962T1
ATE181962T1 AT91919674T AT91919674T ATE181962T1 AT E181962 T1 ATE181962 T1 AT E181962T1 AT 91919674 T AT91919674 T AT 91919674T AT 91919674 T AT91919674 T AT 91919674T AT E181962 T1 ATE181962 T1 AT E181962T1
Authority
AT
Austria
Prior art keywords
sub
gad
provides
cloned
cdna
Prior art date
Application number
AT91919674T
Other languages
English (en)
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24346149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE181962(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE181962T1 publication Critical patent/ATE181962T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT91919674T 1990-09-21 1991-09-23 Klonierte glutaminsäuredekarboxylase ATE181962T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/586,536 US6682906B1 (en) 1990-09-21 1990-09-21 Cloned glutamic acid decarboxylase

Publications (1)

Publication Number Publication Date
ATE181962T1 true ATE181962T1 (de) 1999-07-15

Family

ID=24346149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919674T ATE181962T1 (de) 1990-09-21 1991-09-23 Klonierte glutaminsäuredekarboxylase

Country Status (11)

Country Link
US (3) US6682906B1 (de)
EP (1) EP0502188B1 (de)
JP (3) JPH05503220A (de)
KR (1) KR100220277B1 (de)
AT (1) ATE181962T1 (de)
CA (1) CA2040555C (de)
DE (1) DE69131419T2 (de)
DK (1) DK0502188T3 (de)
ES (1) ES2134199T3 (de)
GR (1) GR3031082T3 (de)
WO (1) WO1992005446A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004632A1 (en) * 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
EP0572478B1 (de) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten
AU1749692A (en) * 1991-05-03 1992-12-21 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
WO1994012529A1 (en) * 1992-12-03 1994-06-09 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
ZA94845B (en) * 1993-02-09 1994-11-11 Univ Monash Methods for the diagnosis of diabetes and prediabetic conditions
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CA2140591A1 (en) 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
SE9401118L (sv) * 1994-03-31 1995-10-01 Synectics Medical Ab GAD, en metod för framställning av modifierat GAD samt en metod för att tillföra modifierat GAD samt peptid
DE4418223A1 (de) 1994-05-25 1995-11-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis des Vorliegens eines Insulin-abhängigen Diabetes mellitus
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
EP0815136B1 (de) 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US5965389A (en) * 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
CA2281949A1 (en) * 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
EP1522591A3 (de) * 1997-02-25 2005-08-17 GTC Biotherapeutics, Inc. Transgen produzierte nicht-sekretierte Proteine
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
WO2000073800A1 (en) * 1999-06-01 2000-12-07 Kyokuto Pharmaceutical Industrial Co., Ltd. Method for assaying anti-gad antibody and kit
CA2409674C (en) * 2000-05-23 2010-05-11 Neurologix, Inc. Glutamic acid decarboxylase (gad) based delivery systems
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
WO2006098485A1 (ja) * 2005-03-15 2006-09-21 Tokyo University Of Science グルタミン酸脱炭酸酵素変異体
BRPI0823327A2 (pt) 2007-03-16 2013-10-22 Genomatica Inc Biocatalisadores microbianos que não ocorrem naturalmente e métodos para a biosíntese de ácido 4-hidroxibutanóico e 1,4-butanodiol
CN101687019A (zh) * 2007-04-24 2010-03-31 迪亚米德治疗股份公司 用于治疗自身免疫性疾病和癌症的药物和方法
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
EP3514242A3 (de) * 2008-09-10 2019-08-28 Genomatica, Inc. Mikroorganismen zur herstellung von 1,4-butandiol
WO2010141920A2 (en) 2009-06-04 2010-12-09 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods
LT2438036T (lt) * 2009-06-04 2017-06-26 Genomatica, Inc. Fermentacijos sultinio komponentų išskyrimo būdas
KR20120083908A (ko) * 2009-10-13 2012-07-26 게노마티카 인코포레이티드 1,4-부탄다이올, 4-하이드록시부탄알, 4-하이드록시부티릴-ｃｏａ, 푸트레신 및 관련 화합물의 제조를 위한 미생물 및 관련 방법
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8445244B2 (en) * 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) * 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
SI2855687T1 (sl) 2012-06-04 2020-09-30 Genomatica, Inc. Mikroorganizmi in metode za proizvodnjo 4-hidroksibutirat, 1,4-butandiola in sorodne spojine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
EP0448635B1 (de) 1988-12-13 1995-09-20 University Of Florida Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm)
NO306996B1 (no) 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
JP2649103B2 (ja) * 1990-08-17 1997-09-03 ユニバーシティー オブ フロリダ インシュリン依存性真性糖尿病の早期検出及び処置のための方法及び組成物
WO1992004632A1 (en) * 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
EP0572478B1 (de) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現

Also Published As

Publication number Publication date
US20050164342A1 (en) 2005-07-28
EP0502188A4 (en) 1994-05-18
DE69131419D1 (de) 1999-08-12
CA2040555A1 (en) 1992-03-22
JP2000333671A (ja) 2000-12-05
US6682906B1 (en) 2004-01-27
CA2040555C (en) 2003-11-04
EP0502188B1 (de) 1999-07-07
EP0502188A1 (de) 1992-09-09
KR920702233A (ko) 1992-09-03
AU657501B2 (en) 1995-03-16
JP2007236390A (ja) 2007-09-20
DK0502188T3 (da) 2000-01-24
JPH05503220A (ja) 1993-06-03
AU8877191A (en) 1992-04-15
US6277586B1 (en) 2001-08-21
GR3031082T3 (en) 1999-12-31
KR100220277B1 (ko) 1999-09-15
ES2134199T3 (es) 1999-10-01
US7329511B2 (en) 2008-02-12
DE69131419T2 (de) 2000-03-30
WO1992005446A1 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
ATE181962T1 (de) Klonierte glutaminsäuredekarboxylase
FI821466A7 (fi) Bacillus-kloonausvektorit, yhdistelmä- DNA-molekyylit, niiden transformoimat Bacillus-isännät sekä menetelmätvieraiden DNA- sekvenssien ekspressiota varten sekä näiden koodaamien polypeptidien tuottamiseksi.
EP0573398A3 (de)
DK0939121T4 (da) TNF-bindende proteiner
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
ATE196164T1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
ES2145059T3 (es) Codificacion y descodificacion de video con movimiento.
CY1106350T1 (el) Εμβολιο φυματιωσης
ES2147178T3 (es) Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
ATE286907T1 (de) Cytokinin-designiertes lerk-5
ES2152251T3 (es) Variantes del dominio lectina de la selectina.
SI1346034T1 (sl) POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA
EP0749442A4 (de) ISOLIERTES p27 PROTEIN UND NUKLEINSÄURE DAFÜR KODIEREND
DK0531300T3 (da) Variant-CD44-overfladeproteiner, DNA-sekvenser, som koder herfor, antistoffer mod disse proteiner samt deres anvendelse til diagnostik og terapi
BR8503237A (pt) Composicao para revestimento reduzivel em agua baseada em uma resina epoxi,processo,e mistura
ES547436A0 (es) Un procedimiento para producir un adn complementario clonadoo su adn modificado que codifica un polipeptido de factor denecrosis de tumores
AU8040898A (en) Type-1 ribosome-inactivating protein
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
MX9203138A (es) Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
AR001014A1 (es) Una molecula de dna aislada que codifica daunorubicina 14-hidroxilasa, dicha daunorubicina 14-hidroxilasa, procedimiento para producir dicho dna,vector que comprende dicho dna, celula huesped que contiene dicho vector, procedimiento para producir doxorubicina mediante dicha celula
CA2049037A1 (en) Aqueous resin preparations and a process for stabilizing rock and plugging cavities
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
PT1012256E (pt) Proteinas de fusao recombinantes baseadas em proteinas de inactividade de ribossomas de visco viscum album

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time